• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress

Apr 08, 2019 8:00am EDT

OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

Apr 02, 2019 8:00am EDT

OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma

Apr 01, 2019 8:00am EDT

OncoSec To Host Key Opinion Leader Symposium On April 5, 2019

Mar 27, 2019 8:16am EDT

OncoSec to Present at the 31st Annual ROTH Conference

Mar 13, 2019 8:30am EDT

OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting

Feb 28, 2019 8:00am EST

OncoSec To Present At BIO CEO & Investor Conference

Feb 08, 2019 8:00am EST

OncoSec Provides KEYNOTE-695 Clinical Update And Outlines 2019 Milestones

Feb 01, 2019 8:00am EST

OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019

Jan 22, 2019 8:00am EST

OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO™ with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer

Jan 07, 2019 8:30am EST
RSS
  • Prev
    • 1...
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • ...45
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    24 N. Main St
    Pennington, NJ 08534

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2022 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.